Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology and pharmaceutical company focused on therapies for pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, and other serious conditions, as well as technologies to expand the availability of transplantable organs. This news page aggregates company announcements, clinical updates, financial disclosures, and conference presentations related to UTHR.
Recent news highlights include detailed results from the TETON-2 phase 3 study of nebulized Tyvaso (treprostinil) Inhalation Solution in idiopathic pulmonary fibrosis, where United Therapeutics reported that the trial met its primary efficacy endpoint and achieved statistically significant improvements in several secondary endpoints. The company has also announced the first clinical xenotransplantation of its investigational UKidney xenokidney in the EXPAND study for patients with end-stage renal disease, reflecting its stated public benefit purpose of expanding access to transplantable organs.
Investors and followers of UTHR can review press releases on quarterly financial results, including product-level revenue disclosures for Tyvaso DPI, nebulized Tyvaso, Remodulin, Orenitram, Unituxin, Adcirca, and other items. Additional updates cover accelerated share repurchase agreements, stock incentive plan changes, and participation in major investor conferences hosted by firms such as J.P. Morgan, UBS, Jefferies, and Bernstein.
For those tracking developments in pulmonary hypertension, interstitial lung disease, xenotransplantation, and the company’s public benefit corporation activities, this news feed offers a centralized view of United Therapeutics’ clinical data presentations, regulatory milestones, and corporate actions. Bookmark this page to quickly access new UTHR press releases and related market-moving information as they are published.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
United Therapeutics Corporation (Nasdaq: UTHR) will report its first quarter 2023 financial results on May 3, 2023, before the market opens. A public webcast will follow at 9:00 a.m. Eastern Time, accessible via the company's website. As a public benefit corporation, United Therapeutics is committed to addressing unmet medical needs and enhancing the availability of transplantable organs through innovative pharmaceutical therapies. The company emphasizes its mission-driven approach, aiming to benefit both patients and stakeholders.
Forward-looking statements regarding their future innovations highlight potential risks and uncertainties that may affect actual results. For detailed information, interested parties can refer to their filings with the Securities and Exchange Commission.
United Therapeutics (NASDAQ: UTHR) has announced that it will present research from its development portfolio at two significant medical conferences: the ISHLT 43rd Annual Meeting and ATS International Conference, both scheduled for April and May 2023, respectively. Key presentations will include findings from the phase 4 ARTISAN study aimed at treating pulmonary arterial hypertension through enhanced treprostinil administration and results from the EXPEDITE study highlighting the positive effects of Remodulin induction prior to Orenitram therapy. The data presented will focus on improving patient outcomes, emphasizing geographical disparities in PAH care, and showcasing the company's innovative xenotransplantation research.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Dr. Martine Rothblatt, CEO and Chairperson, will present an update on the company's business during a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference. The session is scheduled for
United Therapeutics Corporation (Nasdaq: UTHR) announced that President and COO Michael Benkowitz will provide a business overview at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, from 9:10 a.m. to 9:40 a.m. EST. The session will be accessible via a live webcast on the company's website and an archived version will be available for 90 days post-event. United Therapeutics, as a public benefit corporation, focuses on innovative pharmaceutical therapies and technologies for transplantable organs, aiming to meet the medical needs of patients.